Study on the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone for Treating Acute Myeloid Leukemia

Inclusion Criteria

• Must be at least 60 years old.
• Willing and able to follow the study schedule and requirements.
• Have a new diagnosis of acute myeloid leukemia (AML) according to specific medical guidelines.
• Have an IDH1-R132 mutation confirmed by specific genetic tests.
• Have a performance status score between 0 and 3, indicating varying levels of activity.
• White blood cell count must be below 25,000/μL before starting the study treatment.
• Have adequate organ function, including liver and kidney function, as determined by specific blood tests.

Exclusion Criteria

• Have acute promyelocytic leukemia.
• Have previously received ivosidenib or venetoclax.
• Are receiving other experimental cancer treatments, except for certain allowed therapies.
• Have severe, life-threatening complications from leukemia.
• Have an active, uncontrolled infection despite treatment.
• Are planned for a stem cell transplant based on doctor's assessment.
• Have significant heart disease within the last 6 months.
• Have active infections with HIV, hepatitis B, or hepatitis C without improvement.
• Have conditions that affect the ability to swallow or absorb oral medications.
• Have a heart condition that affects the QT interval on an ECG.
• Are not willing to follow contraceptive guidelines during the study.